Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Featured Article 3 Stocks Under $5 With Strong Analyst Upside PotentialReported by Chris Markoch. Article Published: 2/24/2026. 
Key Points - Grab Holdings is gaining analyst support as revenue growth and its first full year of profitability highlight long-term opportunity in Southeast Asia’s expanding digital economy.
- Vaxart offers speculative biotech upside with its oral vaccine platform targeting influenza, norovirus, and COVID-19, creating a high-risk, high-reward setup.
- ThredUp is positioned to benefit from the fast-growing resale market, with strong institutional ownership and industry forecasts pointing to sustained secondhand demand.
- Special Report: [Sponsorship-Ad-6-Format3]
As many investors rotate out of speculative penny stocks, others still embrace the risk-reward dynamic. Stocks trading under $5 carry substantial risk: many are unprofitable and some generate little or no revenue. They are typically small-cap companies, which have been hit hard in recent years. Although the Russell 2000 shows signs of recovery, that improvement hasn't yet spread across the broader small-cap sector. That could change in 2026 if the economic outlook continues to improve, sending money back into speculative names. Even so, as with any market segment, quality matters. A practical filter is positive analyst sentiment — which applies to the three stocks below. Each allows investors to start a sizable position with a modest outlay while still offering the potential for meaningful upside over the next five years. Profitability Milestone Meets Long-Term Emerging Market Growth Emerging market stocks are expected to be among the winners in 2026, although that hasn't been the case so far for Grab Holdings Inc. (NASDAQ: GRAB), which is down about 15% year to date. Grab, based in Singapore, operates a super app that blends technology, e-commerce and fintech services. One factor behind the stock's recent pullback is its proposed merger with Indonesian ride-share rival GoTo. The deal is not final and could be affected by legislative changes in Indonesia that might constrain the company's earnings there. The company also slightly missed top-line expectations in its Q4 2025 earnings report. Still, revenue rose 19% year-over-year, and the period marked the company's first full-year profit. Analysts are forecasting roughly 120% earnings growth over the next 12 months. That helps explain why sentiment remains largely bullish. GRAB stock has a consensus price target of $6.47, implying roughly 54% upside from its current level. High-Risk Biotech With Platform Potential Penny stock investors often look to the biotechnology sector for asymmetric returns. One name to watch is Vaxart Inc. (OTCMKTS: VXRT), the only company on this list that meets the classic definition of a penny stock — at the time of writing it trades just over $0.60 per share. VXRT doesn't have extensive analyst coverage; the sole analyst to rate it in the past 12 months lists it as a Buy with a $2 price target. It's common for many biotech firms to lack broad coverage. Vaxart is a clinical-stage company, meaning all its candidates remain in clinical trials. The potential upside is straightforward: the company is developing oral vaccines primarily for influenza, norovirus and COVID-19. Beyond the convenience and the benefit of avoiding needle aversion, Vaxart says its platform may elicit a broader immune response and therefore wider protection against disease. Institutional ownership in VXRT is relatively low, at about 18%, but in terms of dollar volume inflows have outpaced outflows by nearly 10:1. Resale Tailwinds Could Turn Today's Losses Into Tomorrow's Gains ThredUp Inc. (NASDAQ: TDUP) is down about 33% in 2026, but looking at a longer timeframe shows a different picture: TDUP is up more than 66% over the past 12 months. That suggests the recent decline may be a pullback as investors rotate away from unprofitable companies. In ThredUp's case, caveat "yet" is important. The company operates an online consignment and thrift marketplace that has gained popularity with Gen Z. In its most recent quarter, revenue rose 12.5% year-over-year. ThredUp cites a GlobalData 2025 market survey forecasting the U.S. secondhand market's gross merchandise value to grow at a compound annual growth rate (CAGR) of 9% through 2029. Institutions own an impressive 89% of TDUP. In dollar terms, buying has outpaced selling roughly 2:1, and by number of buyers versus sellers about 3:1. That said, short interest is around 17%, which can add short-term volatility. The consensus price target from six analysts is $12.50, implying more than 190% upside from the current price.
| 
